WALNUT CREEK, Calif. (PRWEB) November 16, 2017 -- MyOncoPath, a new telemedicine clinic specializing in personalized medicine for cancer patients, announced they have begun seeing patients and partnering with medical practices nationwide. MyOncoPath bridges the gap between the millions of cancer patients in the U.S., and genetic counselors specializing in cancer genomics, via its telemedicine clinic, and provides genetic testing recommendations to help providers identify personalized treatment plans.
The field of personalized medicine is progressing rapidly in cancer treatment with new therapeutic agents being tailored to attack an individual’s tumor based on the tumor’s unique genetic makeup, allowing for better targeting and reduced chemotoxicity. With the landscape of cancer treatments and genetic testing changing rapidly, the need for genetic expertise has become more critical to providing the highest quality of care. MyOncoPath has a unique role in the oncology community by both identifying the appropriate genetic testing and connecting providers and patients via telemedicine, allowing access to their services across the United States in compliance with individual state licensing and regulations.
MyOncoPath supports treatment providers, cancer patients, and their family members with a full spectrum of both hereditary and somatic genetic testing, including molecular profiling (or tumor profiling), liquid biopsies, knowledge of clinical trials and new immunotherapies, with various laboratory partners. For patients currently undergoing treatment for cancer, MyOncoPath provides genetic counseling and test recommendations with the aim of identifying targeted treatments and creating a surveillance plan based on the patient’s individual cancer genomic profile.
“MyOncoPath was formed to help improve clinical outcomes for cancer patients immediately. Personalized medicine is available today for patients and providers through genetic testing and diagnostics. The challenge is that most cancer patients and providers aren’t getting access to medical genetics professionals and the relevant testing to personalize medicine today and improve clinical outcomes. The MyOncoPath team is ready to help identify, recommend and interpret genetic tests that can lead to a personalized treatment plan and or promising clinical trials.”
- Ben Harmssen, MyOncoPath’s Board of Directors
MyOncoPath’s board-certified and licensed genetic counselors are uniquely trained to keep abreast of the newest information in the field, evaluate a patient’s history, and facilitate the most informative and cost-effective genetic testing for any given patient. This allows their medical partners to focus on care, knowing sending patients to MyOncoPath provides practitioners additional information regarding the patient’s individual cancer. MyOncoPath offers pre- and post-test counseling by telephone or videoconference, coordination of all genetic testing, and written follow-up, including individualized testing recommendations. Copies of all test results and clinical notes are provided to both patients and their providers.
The genetic counselors at MyOncoPath have a Master of Science in human genetics and counseling, are board certified, and are licensed in the states they serve. MyOncoPath selects genetic counselors with years of experience in the genetic counseling field, specializing in cancer genetics and they are required to maintain credentials through continued comprehensive education.
For more information about MyOncoPath’s genetic counseling services or to learn how to partner with MyOncoPath, please visit http://www.myoncopath.com or contact their offices at 1-888-335-8006 or contact(at)myoncopath(dot)com.
MyOncoPath bridges the gap between the millions of cancer patients and personalized medicine, delivering broader access to genetic testing for cancer patients across the U.S. with the goal of improving clinical outcomes. Headquartered in Walnut Creek, Calif., MyOncoPath’s telemedicine clinic and full spectrum of both hereditary and somatic genetic testing services, provides patients and medical providers with the platform and insights required to identify, plan, discuss and execute, targeted cancer therapies. For more information about MyOncoPath’s genetic counseling services or to learn how to partner with MyOncoPath, please visit http://www.myoncopath.com.
*Ben Harmssen also serves as an Executive Director for Covance Inc. The views expressed in this press release aren’t reflective of the views of Covance Inc. a division of Labcorp.
Andrie Klass, MyOncoPath, https://myoncopath.com/, +1 888-335-8006, [email protected]